PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Suite of Rigorously Validated SOCS Antibodies - SOCS (suppressor of cytokine signaling), as the name implies, belong to a family of proteins that negatively regulates cytokine signaling(1)
AnaSpec Introduces Suite of Rigorously Validated SOCS Antibodies

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2007/01/15 - SOCS (suppressor of cytokine signaling), as the name implies, belong to a family of proteins that negatively regulates cytokine signaling(1).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The structure of each member of the SOCS family consists of a central Src homology 2 (SH2) domain and a SOCS box motif of 40 amino acids on the C-terminus(2,3). The SOCS proteins form part of a classical negative feedback loop that regulates cytokine signal transduction via a STAT-induced transcriptional mechanism(4). Transcription of each of the SOCS genes occurs rapidly in vitro and in vivo in response to cytokines, and once produced, the various members of the SOCS family appear to inhibit signaling in different ways.

AnaSpec has introduced a suite of SOCS antibodies that have been validated in western blots using cell or tissue lysates. These polyclonal antibodies, raised in rabbits and affinity purified, come in a new economical 50 µg format.

Product Size Catalog # Approx MW (kDa) Lysate used in WB
Anti-SOCS-1 50 µg 28132 24 HEK293 (cat# 29520)
Anti-SOCS-2 50 µg 28133 26 Mouse liver (cat# 29509)
Anti-SOCS-3 50 µg 28134 27 MCF-7 (cat# 29519)
Anti-SOCS-4 50 µg 28135 55 Mouse brain (cat# 29507)
Anti-SOCS-5 50 µg 28136 61 A431 (cat# 29514)

For more information, visit our website.

AnaSpec, Inc., located in San Jose, CA, is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

References:

1. Krebs, DL and DJ. Hilton. J. Cell Sci. 113, 2813 (2000)
2. Starr, R. et al. Nature 387, 917 (1997)
3. Hilton, DJ. et al. Proc. Natl. Acad. Sci USA 95, 114 (1998)
4. Yoshimura, A. Cytokine Growth Factor Rev. 9, 197 (1998)

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Suite of Rigorously Validated SOCS Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)